LOREEN (FOURNIER) EVANS, B.S., RPh50 Hungry Hill Road, Sterling, CT 06377

860.564.7399 (H) 860.608.7555 (C)solitaire42@aol.com

CAREER PROFILE

Experienced Pharmacist and Researcher with a track record of success driving operations through communication and service proficiency. Proven ability to increase commercial volume, along with an ability to train personnel on best practices, has led to ongoing career progression. Energetic team player credited with applying hands-on pharmaceutical experience, a passion to continually learn new skills, and industry expertise to drive operations.

AREAS OF STRENGTH AND EXPERTISE

Pharmaceuticals Team Management Inventory and Ordering

Retail and Finance Cross-Functional Skills Interpersonal Communication

Analysis & Reporting Scientific Research RI/CT Certified

PROFESSIONAL EXPERIENCE

CVS 2006 to 2015Retail Pharmacist – Full TimeManaged daily operations of a high-volume pharmacy, accounting for 3,000 scripts week, 6 or more technicians, cashiers, and a drive thru. Oversaw narcotic, control, and non-scheduled drug ordering as well as inventory and record keeping to guarantee best practices and full compliance with state and federal laws. Ran and maintained a robotics system, accurately dispensing the pharmacy’s top 100 fast-moving drugs. Developed and maintained exceptional counseling and interaction skills to ensure a positive customer experience.Key Accomplishments: Increased prescription volume from 1,100 to 1,200 Rx’s as a temporary staff pharmacist at a newer store,

applying interpersonal communication and customer service proficiency to exceed operational goals. Led the district (15+ stores) in customer service evaluations, Rx volume improvement, and refill stats.

Excalibur Powersports 2004 to 2006Director of Retail and FinanceTrained and supervised 10 people in retail and finance divisions of the powersports store. Completed all ordering and paperwork involved in keeping departments operational and productive.Key Accomplishments: Planned, Designed, Set up and Retailed 15,000 sq ft of the store for a time-sensitive retail operation.

Pfizer Central Research 1999 to 2004Senior Scientist, Pharmaceutical R&DComplete projects related to controlled release dosage development with minimal supervision, including the organization, execution, reporting, and presentation of all materials. Directed laboratory experimentation, HPLC, spectrophotometric assays, computer recording functions, and the operation of advanced technical equipment.Key Accomplishments:

Reported project results as the sole representative of the Biopharmaceutics group. Spearheaded the completion of in vivo studies as the primary creator of the Biopharmaceutics team. Established protocols for in vivo studies that were completed for department projects. Hired and organized two laboratory scientists over five years.

Pfizer Central Research 1992 to 1999Scientist, Pharmaceutical R&DServed as a group coordinator for in vivo studies with the Animal Resource Department, Radiation Safety Officer for 156A second floor, Safety Officer for second floor, and in-house coordinator for scintigraphic studies on and off site. Trained new personnel and taught new techniques to other departments.

LOREEN (FOURNIER) EVANS Resume, Page 2

PROFESSIONAL EXPERIENCE CONTINUED

CVS 1990 to 1995Retail Pharmacist – Part TimeDispensed prescriptions, mastered computer systems, and finalized all essential records. Trained new pharmacy students while assisting several CT CVS stores. Opened and closed locations and tackled all assigned tasks.Key Accomplishments: Acclaimed as a high-volume pharmacist, recognized for success with both customers and coworkers.

ADDITIONAL WORK HISTORY

Pfizer Central Research 1983 to 1992Associate Scientist, Pharmaceutical R&D (1989 to 1992) Assistant Scientist, Pharmaceutical R&D (1983 to 1989)

EDUCATION AND TRAINING

Bachelor of Science, Pharmacy, University of Rhode Island, Kingston, RILicensed Pharmacist State of Rhode IslandLicensed Pharmacist State of ConnecticutAALAS Certified Animal Handler (Pfizer)

Pharmacokinetics for Pharmaceutical Scientists, University of California, San Francisco (1992)Recent Advances in the In Vivo Evaluation of Dosage Forms and Drug Phenomena (AAPS, 1994)Technical Writing in a Research Environment (Pfizer, 1996)HPLC Workshop With Practical Information for Chromatographers (Pfizer, sponsored by MacMod, 1996)Introduction to Mass Spectrophotometry (Pfizer, half day course, 1997)American Association of Laboratory Animal Science, National Certification Course (1998)

ACADEMIC AND PROFESSIONAL HONORS

Pfizer Achievement Award Winner, 1990Rho Chi Society

VOLUTEERISM

Pharm R&D United Way, CoordinatorFund Raiser for the “Pony Express,” Susan G. Komen Breast Cancer FoundationFund Raiser for local charities: Phoenix House, TCCVA, Delta Society, CT., Make a Wish Foundation, etc.Annual Fundraiser for Americade, “Ride For Kids,” 1999-2007Americade, Activity and Fundraiser Volunteer (15 years)Several Horse Clubs and AssociationsN.E.R.R. MemberDog and Cat RescueFibromyalgia AwarenessBreast Cancer Awareness

LOREEN (FOURNIER) EVANS, B.S., RPh

LOREEN (FOURNIER) EVANS Resume, Page 350 Hungry Hill Road, Sterling, CT 06377

860.564.7399 (H) 860.608.7555 (C)solitaire42@aol.com

PUBLICATIONS

1. Thombre, A.G., Cardinal, J.R. and Fournier, L.A. (1992) “A Delivery Device Containing a Poorly Drug in a Hydrophobic Medium, Ruminal Delivery Application.” Journal of Controlled Release 18; 221-233.

2. Sutton, S. C., L. Fournier, et al. (1995). "Dog colonoscopy model for predicting human colon absorption." Pharm Res 12(9): S221.

3. Sutton, S., L. Evans, et al. (1996). “Predicting Injection Site Muscle Damage I: Evaluation of Immediate Release Parenteral Formulations in Animal Models.” Pharmaceutical Research 13(10): 1507-1513.

4. Sutton, S., L. Evans, et al. (1996). “Predicting Injection Site Muscle Damage II: Evaluation of Extended Release Parenteral Formulations in Animal Models.” Pharmaceutical Research 13(10): 1514-1518.

5. Evans, L., Sutton, S., et al. (1996). “Predicting Injection Site Muscle Damage III: Evaluation of Intramuscular Formulations in the L6 Cell Model.” Pharmaceutical Research 13(10): 1585-1587.

6. Sutton, S. C., K. Norton, Evans, L.A.F. (1997). "In vivo evaluation of Compound A capsule storage conditions." Pharm Res 14.

7. Sutton, S., K. Norton, Evans, L.A.F. (1999). "Evaluation of stressed and control hard gelatin capsules containing tenidap in the dog." J. Pharm. Sci.

8. Sutton, S., K. Norton, Evans, L.A.F. (1999). "Evaluation and validation of the dog colonoscope model for predicting absorption of compounds from the human colon." Pharmaceutical Sciences Online Journal 1(2).

9. Evans, L., Sutton. S, (1999) “The use of the dog to predict food effect for ziprasidone in humans: comparison of low and high fat meals.” Pharm Res 16.

10. Sutton, S., K. Norton, Evans, L. (1999). "Evaluation and validation of the dog colonoscope model for predicting absorption of compounds from the human colon." Pharmaceutical Sciences Online Journal 1(2).

11. Evans, L. (2000).”Lessons learned from canine scintigraphic pharmacokinetic studies (1996-1999)”. Groton, PGRD.

12. Evans, L. (2000). Colon degradation model. Groton, PGRD.

POSTERS

Gumkowski, M.J., Fournier, L.A., Tierney, N.K. and Curatolo, W.J. “Improved Bioavailability through use of Soft Gelatin Capsule Formulations of Terlakiren, A Tripeptide Renin Inhibitor. NERPA Meeting, (1994)

Evans, L.A.F, Sutton, S.C., Norton, K.A., Rinaldi, M.T.S.: Animal models for predicting injection site muscle damage: I. Evaluation of immediate release parenteral formulations. NERPA Meeting, 1994.

LOREEN (FOURNIER) EVANS Resume, Page 4

POSTERS CONT.

Evans, L.A.F, Sutton, S.C., Norton, K.A., Rinaldi, M.T.S.: Animal models for predicting injection site muscle damage: I. Evaluation of immediate release parenteral formulations. AAPS Meeting, San Diego, CA 1994.

Sutton, S.C., Evans, L.A.F., Norton, K.A., Rinaldi, M.T.S.: Animal models for predicting injection site muscle damage: II. Evaluation of extended release parenteral formulations. NERPA Meeting , 1994

Sutton, S.C., Evans, L.A.F., Norton, K.A., Rinaldi, M.T.S.: Animal models for predicting injection site muscle damage: II. Evaluation of extended release parenteral formulations. AAPS Meeting, San Diego, CA, 1994.

Sutton, SC, Evans, LAF, Norton KA: Dog colonoscopy model for predicting human colon absorption. AAPS Meeting, Miami, FL, 1995.

Gumkowski, M., Appleton, T., Tierney, N, Evans, LAF, et. al. “Oral Bioavailability Improvement Strategies for Tripeptide Renin Inhibitors.” 211th Annual Meeting of the American Chemical Society, New Orleans, LA (1996)

Evans, LAF, Sutton, SC, “Scintigraphy.”

Sutton, SC, Norton, KA, Evans, LAF: In Vivo Evaluation Of Compound A Capsule Storage Conditions. AAPS, Boston, 1997.

Norton, K.A.N., Evans, L.A.F., and Sutton, S.C. “Comparison of the Dog Colon and CACO-2 Models as Predictors of Human Colonic Absorption. AAPS meeting, Boston, MA (1997)

Evans, L.A.F., M.T. am Ende, R.M. Beihn, R.B. Gaskin, M. Jay, K.A. Norton, S.C. Sutton, S. Warren, “Use of Scintigraphy as a Tool in The Development of in Vitro-In Vivo Relationships (IVIVR) For Controlled Release Formulations” AALAS National Meeting, Indianapolis, IN November (1999).

IN-HOUSE POSTERS

1. Models for Predicting Tissue Damage of Intramuscular Formulations. Presented at the Pharm R&D Poster Coffee, July, 1993.

2. Evans, L. A. F., E. M. Gibbs, P. E. Genereux, and S. C. Sutton: The Evaluation of an L-6 Cell Model for Predicting Injection Site Damage of Intramuscular Formulations. Presented at the Pharm R&D Poster Coffee, July, 1995.

3. Evans, LAF, KA Norton, SC Sutton, MT am Ende, MJ Puz: Use of gamma scintigraphy as a tool in the development of in vitro-in vivo relationships (IVIVR) of sertraline controlled release formulations in dogs. Presented at Developmental Year End Poster Session, 1996.

4. L.A. Evans, K.A. Norton, and S.C. Sutton, “Use of Gamma Scintigraphy As A Tool To Flush Out Fatal Flaws in Formulations”. Presented at Pharm R & D Poster Coffee, March, 1997.

5. K.A. Norton, L.A. Evans, and S.C. Sutton, “Comparison of The Dog Colon And Caco-2 Models As Predictors Of Human Colonic Absorption”. Presented at Pharm R & D Poster Coffee, March, 1997.

6. L.A.F. Evans, S.C. Sutton, “Choice of Meal for Canine Studies To Predict the Food Effect Observed in Humans” Presented at Pharm R & D Poster Coffee, March 1999.

LOREEN (FOURNIER) EVANS Resume, Page 5

IN-HOUSE POSTERS CONT.

7. L.A.F. Evans, S.C. Sutton, “Choice of Meal for Canine Studies To Predict the Food Effect Observed in Humans” Presented at Developmental Year End Poster Session, 1999.

8. L.A.F. Evans, “Biopharmaceutics Group, Who We Are and What We Do”, Instructional Course for New Employees, September, 1999.

9. E.M. Greer, B.R. Eldridge, B.B. Huff, L.A.F. Evans, J.E. Mertz and M.J. Gumkowski, “Pharm R&D Compound Handling Guidelines for Laboratory Processes” Presented at Developmental Year End Poster Session, 1999.

10. F. Dumont, M.J. Puz, L.A. Evans, B.A. Johnson, L.A. Miller, and K. Waterman, “The Oral Drug Delivery Technology Discussion Group: A Stimulating and Open Forum For the Exchange of New Ideas”, Presented at Developmental Year End Poster Session, 1999.

11. S. C. Sutton, L.A.F. Evans, K.A. Norton, and J.M. McCarthy, “Team Biopharmaceutics”, Presented at the Developmental Year End Poster Session, 1999.

12. L.A.F. Evans, S.C. Sutton, “Choice of a Meal for Canine Studies To Predict the Food Effect in Humans” Presented at year end Poster Session, 12/14/ 99.

13. L.A.F. Evans, H.L. Carter, S.C. Sutton, A.G. Thombre,” Choosing an Efflux Inhibitor for Enhancing the Bioavailability of Azithromycin”, Presented at Pharm R&D Poster Session March 13, 2002.